Pharmaceutical giant Novo Nordisk (NVO) stock falls on Friday after receiving mixed data on its new oral weight-loss pill — the cannabinoid receptor Monlunabant — and is ramping up the injectable price competition with rival Eli Lilly (LLY).

Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination to dig into the details of Novo's CB1 weight-loss pill and discuss how the company is looking to bring down the cost of its GLP-1 weight-loss injectables, Ozempic and Wegovy.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan and updated by Melanie Riehl